1
|
Kelly JR, Martini S, Brownlow N, Joshi D, Federico S, Jamshidi S, Kjaer S, Lockwood N, Rahman KM, Fraternali F, Parker PJ, Soliman TN. The Aurora B specificity switch is required to protect from non-disjunction at the metaphase/anaphase transition. Nat Commun 2020; 11:1396. [PMID: 32170202 PMCID: PMC7070073 DOI: 10.1038/s41467-020-15163-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Accepted: 02/21/2020] [Indexed: 12/22/2022] Open
Abstract
The Aurora B abscission checkpoint delays cytokinesis until resolution of DNA trapped in the cleavage furrow. This process involves PKCε phosphorylation of Aurora B S227. Assessing if this PKCε-Aurora B module provides a more widely exploited genome-protective control for the cell cycle, we show Aurora B phosphorylation at S227 by PKCε also occurs during mitosis. Expression of Aurora B S227A phenocopies inhibition of PKCε in by-passing the delay and resolution at anaphase entry that is associated with non-disjunction and catenation of sister chromatids. Implementation of this anaphase delay is reflected in PKCε activation following cell cycle dependent cleavage by caspase 7; knock-down of caspase 7 phenocopies PKCε loss, in a manner rescued by ectopically expressing/generating a free PKCε catalytic domain. Molecular dynamics indicates that Aurora B S227 phosphorylation induces conformational changes and this manifests in a profound switch in specificity towards S29 TopoIIα phosphorylation, a response necessary for catenation resolution during mitosis.
Collapse
Affiliation(s)
- Joanna R Kelly
- Protein Phosphorylation Laboratory, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
- Cancer Research UK, Manchester Institute, Alderley Park, SK10 4TG, UK
| | - Silvia Martini
- Protein Phosphorylation Laboratory, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
| | - Nicola Brownlow
- Protein Phosphorylation Laboratory, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
- Instituto de Neurociencias, Av. Santiago Ramón y Cajal s/n 03550, San Juan de Alicante, Spain
| | - Dhira Joshi
- Peptide Chemistry Platform, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
| | - Stefania Federico
- Peptide Chemistry Platform, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
| | - Shirin Jamshidi
- School of Cancer and Pharmaceutical Sciences, King's College London, London, UK
| | - Svend Kjaer
- Structural Biology Platform, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
| | - Nicola Lockwood
- Protein Phosphorylation Laboratory, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
| | | | - Franca Fraternali
- Randall Centre for Cell and Molecular Biophysics, King's College London, London, UK
| | - Peter J Parker
- Protein Phosphorylation Laboratory, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.
- School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
| | - Tanya N Soliman
- Protein Phosphorylation Laboratory, Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.
- Barts Cancer Institute, Queen Mary University London, Charterhouse Square, London, EC1M 6BE, UK.
| |
Collapse
|
2
|
Ferreli C, Lai C, August S, Buggy Y, Kumar P, Brownlow N, Parker P, Friedmann PS, Ardern-Jones M, Pickard C, Healy E. STAT4 expression and activation is increased during mitosis in vitro and in vivo in skin- and mucosa-derived cell types: implications in neoplastic and inflammatory skin diseases. J Eur Acad Dermatol Venereol 2017; 31:1663-1673. [PMID: 28516569 DOI: 10.1111/jdv.14342] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 04/19/2017] [Indexed: 02/11/2024]
Abstract
BACKGROUND The signal transducer and activator of transcription-4 (STAT4/Stat4) is a transcription factor known to convey signals from interleukin-12, interleukin-23, and interferon-alpha/beta to the nucleus, resulting in activation of dendritic cells, T-helper cell differentiation and production of interferon-gamma. OBJECTIVE To demonstrate a novel role for STAT4 in cell mitosis. RESULTS Phosphoserine STAT4 (pSerSTAT4) is increased in cells undergoing mitosis and is distributed throughout the cytoplasm during this stage of the cell cycle, whilst phosphotyrosine STAT4 (pTyrSTAT4) is confined to the chromosomal compartment. This distinct pattern of pSerSTAT4 during mitosis is seen in vitro in human keratinocytes and in other cell types. This is also present in vivo in cells undergoing mitosis in normal skin, psoriasis and squamous cell carcinoma. Inhibition of STAT4 phosphorylation by lisofylline and depletion of STAT4 by RNA interference results in a delay in progression of mitosis and leads to a reduction in cells completing cytokinesis. CONCLUSION Our data demonstrate that STAT4 plays a role in enabling the normal and timely division of cells undergoing mitosis.
Collapse
Affiliation(s)
- C Ferreli
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
- Dermatology Unit, Department of Medical Sciences, Public Health University of Cagliari, Cagliari, Italy
| | - C Lai
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
- Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK
| | - S August
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
- Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK
| | - Y Buggy
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
| | - P Kumar
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
| | - N Brownlow
- London Research Institute, Lincoln's Inn Fields, London, UK
| | - P Parker
- London Research Institute, Lincoln's Inn Fields, London, UK
| | - P S Friedmann
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
- Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK
| | - M Ardern-Jones
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
- Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK
| | - C Pickard
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
| | - E Healy
- Dermatopharmacology, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK
- Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK
| |
Collapse
|
3
|
Pike T, Brownlow N, Kjaer S, Carlton J, Parker PJ. PKCɛ switches Aurora B specificity to exit the abscission checkpoint. Nat Commun 2016; 7:13853. [PMID: 28004745 PMCID: PMC5192180 DOI: 10.1038/ncomms13853] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 11/03/2016] [Indexed: 01/21/2023] Open
Abstract
The 'NoCut', or Aurora B abscission checkpoint can be activated if DNA is retained in the cleavage furrow after completion of anaphase. Checkpoint failure leads to incomplete abscission and a binucleate outcome. These phenotypes are also observed after loss of PKCɛ in transformed cell models. Here we show that PKCɛ directly modulates the Aurora B-dependent abscission checkpoint by phosphorylating Aurora B at S227. This phosphorylation invokes a switch in Aurora B specificity, with increased phosphorylation of a subset of target substrates, including the CPC subunit Borealin. This switch is essential for abscission checkpoint exit. Preventing the phosphorylation of Borealin leads to abscission failure, as does expression of a non-phosphorylatable Aurora B S227A mutant. Further, depletion of the ESCRT-III component and Aurora B substrate CHMP4C enables abscission, bypassing the PKCɛ-Aurora B exit pathway. Thus, we demonstrate that PKCɛ signals through Aurora B to exit the abscission checkpoint and complete cell division.
Collapse
Affiliation(s)
- Tanya Pike
- Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Nicola Brownlow
- Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Svend Kjaer
- Protein Purification Facility, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Jeremy Carlton
- Division of Cancer Studies King's College London, New Hunt's House, Guy's Campus, London SE1 1UL, UK
| | - Peter J. Parker
- Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
- Division of Cancer Studies King's College London, New Hunt's House, Guy's Campus, London SE1 1UL, UK
| |
Collapse
|
4
|
Affiliation(s)
- Nuno Amaral
- a Centre for Genomic Regulation (CRG) , The Barcelona Institute of Science and Technology , Barcelona , Spain.,b Universitat Pompeu Fabra (UPF) , Barcelona , Spain
| | - Nicola Brownlow
- a Centre for Genomic Regulation (CRG) , The Barcelona Institute of Science and Technology , Barcelona , Spain.,b Universitat Pompeu Fabra (UPF) , Barcelona , Spain
| | - Manuel Mendoza
- a Centre for Genomic Regulation (CRG) , The Barcelona Institute of Science and Technology , Barcelona , Spain.,b Universitat Pompeu Fabra (UPF) , Barcelona , Spain
| |
Collapse
|
5
|
Brownlow N, Pike T, Zicha D, Collinson L, Parker PJ. Mitotic catenation is monitored and resolved by a PKCε-regulated pathway. Nat Commun 2014; 5:5685. [PMID: 25483024 PMCID: PMC4272242 DOI: 10.1038/ncomms6685] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 10/27/2014] [Indexed: 12/15/2022] Open
Abstract
Exit from mitosis is controlled by silencing of the spindle assembly checkpoint (SAC). It is important that preceding exit, all sister chromatid pairs are correctly bioriented, and that residual catenation is resolved, permitting complete sister chromatid separation in the ensuing anaphase. Here we determine that the metaphase response to catenation in mammalian cells operates through PKCε. The PKCε-controlled pathway regulates exit from the SAC only when mitotic cells are challenged by retained catenation and this delayed exit is characterized by BubR1-high and Mad2-low kinetochores. In addition, we show that this pathway is necessary to facilitate resolution of retained catenanes in mitosis. When delayed by catenation in mitosis, inhibition of PKCε results in premature entry into anaphase with PICH-positive strands and chromosome bridging. These findings demonstrate the importance of PKCε-mediated regulation in protection from loss of chromosome integrity in cells failing to resolve catenation in G2.
Collapse
Affiliation(s)
- Nicola Brownlow
- Protein Phosphorylation Laboratory, Cancer Research UK London
Research Institute, 44 Lincolns Inn Fields, London
WC2A 3LY, UK
| | - Tanya Pike
- Protein Phosphorylation Laboratory, Cancer Research UK London
Research Institute, 44 Lincolns Inn Fields, London
WC2A 3LY, UK
| | - Daniel Zicha
- Light Microscopy, Cancer Research UK London Research
Institute, London, WC2A 3LY, UK
| | - Lucy Collinson
- Electron Microscopy, Cancer Research UK London Research
Institute, London
WC2A 3LY, UK
| | - Peter J. Parker
- Protein Phosphorylation Laboratory, Cancer Research UK London
Research Institute, 44 Lincolns Inn Fields, London
WC2A 3LY, UK
- Division of Cancer Studies, King’s College London,
New Hunt’s House, Guy’s Campus, London
SE1 1UL, UK
| |
Collapse
|
6
|
Abstract
Cytokinesis is the final act of the cell cycle where the replicated DNA and cellular contents are finally split into two daughter cells. This process is very tightly controlled as DNA segregation errors and cytokinesis failure is commonly associated with aneuploidy and aggressive tumours. Protein kinase Cε (PKCε) is a lipid-activated serine/threonine kinase that is part of the PKC superfamily. PKCε plays a complex role in the regulation of migration, adhesion and cytokinesis and in the present article we discuss the interplay between these processes. Integrin-mediated interaction with the actin cytoskeleton is a known regulator of cell adhesion and migration and there is emerging evidence that this pathway may also be essential for cytokinesis. We discuss evidence that a known actin-binding region in PKCε is involved in PKCε-mediated regulation of cytokinesis, providing a link between integrin-mediated stabilization of the cytokinesis furrow and PKCε recruitment.
Collapse
Affiliation(s)
- Nicola Brownlow
- *Protein Phosphorylation Laboratory, Cancer Research UK London Research Institute, London WC2A 3LY, U.K
| | - Tanya Pike
- *Protein Phosphorylation Laboratory, Cancer Research UK London Research Institute, London WC2A 3LY, U.K
| | - Victoria Crossland
- *Protein Phosphorylation Laboratory, Cancer Research UK London Research Institute, London WC2A 3LY, U.K
| | - Jeroen Claus
- *Protein Phosphorylation Laboratory, Cancer Research UK London Research Institute, London WC2A 3LY, U.K
| | | |
Collapse
|
7
|
Skobridis K, Kinigopoulou M, Theodorou V, Giannousi E, Russell A, Chauhan R, Sala R, Brownlow N, Kiriakidis S, Domin J, Tzakos A, Dibb N. Novel Imatinib Derivatives with Altered Specificity between BcrâAbl and FMS, KIT, and PDGF Receptors. ChemMedChem 2010; 5:130-9. [DOI: 10.1002/cmdc.200900394] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
8
|
Abstract
Cell division requires the separation and partitioning of sister chromatids to opposite ends of the cell before an actomyosin ring contracts the membrane in between during cytokinesis. The final irreversible step occurs during abscission when the ring breaks down and the membrane is sealed in its place. The physical mechanics of contraction depend on RhoA, which is stimulated by a centralspindlin complex around the cell equator. However exactly how these events are reversed to allow actomyosin breakdown and abscission were not well understood. Here we will discuss new findings that implicate Protein Kinase C epsilon (PKCepsilon) as a regulator of RhoA signalling required for abscission.
Collapse
Affiliation(s)
- Adrian T Saurin
- Protein Phosphorylation Laboratory, London Research Institute, Cancer Research UK, London, UK
| | | | | |
Collapse
|
9
|
Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2008; 23:590-4. [PMID: 18784745 DOI: 10.1038/leu.2008.237] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
10
|
Brownlow N, Vaid M, Dibb NJ. Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. Leukemia 2008; 22:1452-3. [DOI: 10.1038/sj.leu.2405085] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Brownlow N, Russell AE, Saravanapavan H, Wiesmann M, Murray JM, Manley PW, Dibb NJ. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2007; 22:649-52. [PMID: 17851554 DOI: 10.1038/sj.leu.2404944] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
12
|
Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2005; 25:147-51. [PMID: 16170366 DOI: 10.1038/sj.onc.1209007] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The kinase inhibitor imatinib is used in the treatment of chronic myeloid leukaemia, where it targets the intracellular Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumours, where it targets either the KIT or PDGF tyrosine kinase receptors. Here, we report that imatinib is also an effective inhibitor of the closely related FMS receptor for macrophage colony stimulating factor and that mutation of Asp 802 of FMS to Val confers imatinib resistance. Imatinib readily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the oncogene v-fms and also inhibited the growth of the Bacl.2F5 macrophage cell line. The cellular IC50 value of imatinib for FMS was similar to those for Bcr-Abl and KIT. Consequently, imatinib may also prove effective for the treatment of diseases whose progression is dependent upon macrophage-colony stimulating factor, this includes certain aspects of cancer and inflammation.
Collapse
Affiliation(s)
- J R Taylor
- Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, London, UK
| | | | | | | |
Collapse
|